Form 4: Intra-Cellular Therapies EVP Suresh K. Durgam Reports Stock Transactions

EVP and Chief Medical Officer of Intra-Cellular Therapies, Suresh K. Durgam, reports the vesting and tax withholding of restricted stock units.

Summary

• Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, reported transactions involving common stock and restricted stock units.
• On March 6, 2025, 13,133 restricted stock units vested and converted into common stock.
• Also on March 6, 2025, 5,572 shares were withheld by the issuer to cover tax obligations at a price of $131.19.
• On March 10, 2025, 7,345 restricted stock units vested and converted into common stock.
• Additionally, on March 10, 2025, 3,116 shares were withheld for tax obligations at a price of $131.24.
• Following these transactions, Durgam directly owns 42,913 shares of common stock.

Sentiment

Score: 5

Explanation: This is a routine insider transaction report, reflecting scheduled vesting of stock options and subsequent tax withholding. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider activity and can be monitored for insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• Shareholders may monitor these filings for insights into management's actions.
• The transactions have a minor dilutive effect due to the issuance of new shares upon vesting.

Key Dates